You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

11 Results
Drug
Other Name(s): Vesanoid®
Jun 2019
Drug
Other Name(s): Thalomid®
Jun 2019
Drug
Other Name(s): Lanvis®
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Intent: Palliative
May 2019
Regimen
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
May 2019
Guidelines and Advice
Updated
Jan 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Feb 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
High Cost Therapy Funding Program
    Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma
Updated
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Updated
Mar 2026